Xenomics Presents New Diagnostics Platform: Detection Of In Vivo Cell Death By Analysis Of Cell-Free Tissue-Specific MiRNA In Urine Or Blood

Xenomics, Inc. (XNOM.PK), a developer of non-invasive, next-generation molecular diagnostics, announces that Dr. Samuil Umansky, Chief Scientific Officer, is scheduled to give a talk today at the “microRNA in Human Disease and Development” conference in Boston, MA. Dr. Umansky will present a new platform technology developed by the company for detection of in vivo cell death by quantitative analysis of miRNA from urine and other bodily fluids.

More: continued here

Filed under: Stem Cell Research on March 31st, 2009